

**ASX RELEASE**

**8 June 2021**

**Change of Director's Interest Notice – Appendix 3Y: Dr John Lambert**

Appendix 3Y Change of Director's Interest Notice for Dr. John Lambert is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

**For further information:**

Andrew J. Cooke  
Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Amplia Therapeutics Limited</b>
<b>ABN</b>	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>John Nicholas Lambert</b>
<b>Date of last notice</b>	5 August 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>LLAC Investments Pty Ltd &lt;Ralph Super Fund A/C&gt;</b> of which Dr. Lambert is a Director and beneficiary.  <b>Parallax Consulting Pty Ltd</b> of which Dr. Lambert is a Director and a beneficiary.
<b>Date of change</b>	7 June 2021

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p>Direct:  1,200,000 Options  (i) Exercise Price: \$0.155 (altered price – refer Notice Pursuant to ASX LR 3.11.2 lodged with ASX 2 November 2020)  (ii) 4 years vesting (accelerated upon completion of Phase 1 trial);  (iii) Fully vested in a change of control;  (iv) Expire 24 June 2024.</p> <p>Indirect:  220,000 fully paid shares  50,000 Options – Exercise Price \$0.15 Expiry Date 30 June 2022  750,000 Options – Exercise Price \$0.60 Expiry Date 31 August 2022</p>
<p><b>Class</b></p>	<p>Fully Paid Ordinary Shares</p>
<p><b>Number acquired</b></p>	<p>130,000 Shares (Issued upon Exercise of Options)</p>
<p><b>Number disposed</b></p>	<p>130,000 Options (Exercise of Options)</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$0.155 per share (Option Exercise Price)</p>
<p><b>No. of securities held after change</b></p>	<p>Direct:  1,070,000 Options  (v) Exercise Price: \$0.155  (vi) 4 years vesting (accelerated upon completion of Phase 1 trial);  (vii) Fully vested in a change of control;  (viii) Expire 24 June 2024.</p> <p>130,000 fully paid shares</p> <p>Indirect:  220,000 fully paid shares  50,000 Options – Exercise Price \$0.15 Expiry Date 30 June 2022  750,000 Options – Exercise Price \$0.60 Expiry Date 31 August 2022</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of Options (Exercise Price \$0.155, Expiry Date 24 June 2024)
--	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

8 June 2021

---

<sup>+</sup> See chapter 19 for defined terms.